Lilly and Novo Nordisk Face Setback as Medicare GLP-1 Pilot Delayed
The Centers for Medicare and Medicaid Services (CMS) has postponed the pilot run of its BALANCE financing model, which aimed to improve access to GLP-1 weight-loss drugs. The delay follows reluctance from major insurers like CVS and UnitedHealth to participate. The BALANCE program was designed to negotiate drug prices directly with manufacturers to make these medications more affordable. The postponement has negatively impacted the stock prices of Eli Lilly and Novo Nordisk, key players in the obesity drug market. 
